Seres Therapeutics announced that its stockholders voted to approve the previously announced proposed sale of the Company’s VOWST business to Societe des Produits Nestle S.A. Seres will file a Current Report on Form 8-K with the SEC which details the voting results. The transaction is expected to close on September 30, 2024, subject to the satisfaction of customary closing conditions.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MCRB:
- Seres Therapeutics’ SER-155 Shows Promising Clinical Results
- Seres Therapeutics reports data from Cohort 2 of SER-155 Phase 1b study
- Biotech Alert: Searches spiking for these stocks today
- Seres Therapeutics strength attributed to Betaville rumor mention
- Seres Therapeutics Releases Financial Statements Ahead of Asset Sale